Quince Therapeutics, Inc. is a leading late-stage biotechnology company focused on utilizing a patient's own biology to develop groundbreaking therapeutics for rare diseases. With the recent acquisition of EryDel S.

p. A., Quince is dedicated to advancing treatments, particularly targeting Ataxia-Telangiectasia (A-T), where there are currently no approved therapies worldwide. Their Phase 3 lead asset, EryDex, utilizes the innovative AIDE technology platform for autologous intracellular drug encapsulation, offering a monthly treatment solution for patients.

Quince's commitment to rare disease research is evident through their strategic development efforts to address unmet medical needs. Led by CEO Dirk Thye, Quince is on a mission to create a lasting impact on the lives of individuals and families affected by debilitating diseases. Stay informed about Quince's advancements in therapeutics by following their latest news releases.

Join Quince in revolutionizing rare disease treatment